Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ejhf.74 http://scihub22266oqcxt.onion/10.1002/ejhf.74 C4659502!4659502 !24599738     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24599738 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Eur+J+Heart+Fail 2014 ; 16 (5 ): 471-82 Nephropedia Template TP {{tp|p=24599738 |t=2014. Decongestion in acute heart failure |pdf=|usr=}}{{24599738 }} gab.com Text Decongestion in acute heart failure JO: Eur J Heart Fail http://www.kidney.de/pget.php?&tw=1&pmid=24599738 #FOAvip Congestion is a major reason for hospitalization in acute heart failure (HF). Therapeutic strategies to manage congestion include diuretics, vasodilators, ultrafiltration, vasopressin antagonists, mineralocorticoid receptor antagonists, and potentially also novel therapies such as gut sequesterants and serelaxin. Uncertainty exists with respect to the appropriate decongestion strategy for an individual patient. In this review, we summarize the benefit and risk profiles for these decongestion strategies and provide guidance on selecting an appropriate approach for different patients. An evidence-based initial approach to congestion management involves high-dose i.v. diuretics with addition of vasodilators for dyspnoea relief if blood pressure allows. To enhance diuresis or overcome diuretic resistance, options include dual nephron blockade with thiazide diuretics or natriuretic doses of mineralocorticoid receptor antagonists. Vasopressin antagonists may improve aquaresis and relieve dyspnoea. If diuretic strategies are unsuccessful, then ultrafiltration may be considered. Ultrafiltration should be used with caution in the setting of worsening renal function. This review is based on discussions among scientists, clinical trialists, and regulatory representatives at the 9th Global Cardio Vascular Clinical Trialists Forum in Paris, France, from 30 November to 1 December 2012. Twit Text FOAVip Decongestion in acute heart failure ????Eur J Heart Fail http://www.kidney.de/pget.php?&tw=1&pmid=24599738 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24599738 #FOAvip English Wikipedia <ref>{{Cite pmid|24599738 }}</ref> Decongestion in acute heart failure #MMPMID24599738 Mentz RJ ; Kjeldsen K ; Rossi GP ; Voors AA ; Cleland JG ; Anker SD ; Gheorghiade M ; Fiuzat M ; Rossignol P ; Zannad F ; Pitt B ; O'Connor C ; Felker GM Eur J Heart Fail 2014[May]; 16 (5 ): 471-82 PMID24599738 show ga Congestion is a major reason for hospitalization in acute heart failure (HF). Therapeutic strategies to manage congestion include diuretics, vasodilators, ultrafiltration, vasopressin antagonists, mineralocorticoid receptor antagonists, and potentially also novel therapies such as gut sequesterants and serelaxin. Uncertainty exists with respect to the appropriate decongestion strategy for an individual patient. In this review, we summarize the benefit and risk profiles for these decongestion strategies and provide guidance on selecting an appropriate approach for different patients. An evidence-based initial approach to congestion management involves high-dose i.v. diuretics with addition of vasodilators for dyspnoea relief if blood pressure allows. To enhance diuresis or overcome diuretic resistance, options include dual nephron blockade with thiazide diuretics or natriuretic doses of mineralocorticoid receptor antagonists. Vasopressin antagonists may improve aquaresis and relieve dyspnoea. If diuretic strategies are unsuccessful, then ultrafiltration may be considered. Ultrafiltration should be used with caution in the setting of worsening renal function. This review is based on discussions among scientists, clinical trialists, and regulatory representatives at the 9th Global Cardio Vascular Clinical Trialists Forum in Paris, France, from 30 November to 1 December 2012. |*Cardiovascular Agents/classification/therapeutic use [MESH] |*Heart Failure/physiopathology/therapy [MESH] |Acute Disease [MESH] |Disease Management [MESH] |Dyspnea/therapy [MESH] |Evidence-Based Practice [MESH] |Humans [MESH] |Outcome Assessment, Health Care [MESH] |Patient Selection [MESH] |Practice Guidelines as Topic [MESH]Decongestion in acute heart failure (epmc).pdf DeepDyve Pubget Overpricing